Doug Hirsch : Thank you, Trevor. Yeah, engagement is obviously a significant priority for us. If you go back in the history of good Iraq, so originally you know when we were a small brand and people didn’t know us we tried to get people on the site. You know simple experience, search for a drug, get a coupon, find savings, so we could establish that trust and value of consumers. If you look forward, it’s been €“ you know 12 plus years we’ve been doing this. We have that trust, we have that 90 MPS, and we have the opportunity to engage users and drive a higher LTV for us. I’m proud to say as I think Karsten had mentioned previously that we doubled our portion of transactions attached to fully engage users in the second half of €˜22.
And when we have that, those fully engaged users, we could do incredibly cool things. For example, a medicine cabinet. So if you haven’t downloaded our app recently, I strongly recommend you check it out. You can actually see a visual representation of your medicine, your actual medicine cabinet on the app, and then we can do exciting things to drive engagement and adherence like push notifications for refill reminders or pricing changes. We believe that these will drive better adherence, better patient outcomes and obviously lift LTV too. So we’re really, really excited about some of the engagement issues. I’ll throw it to Karsten for some of the financial perspective on it.
Karsten Voermann: Thanks Doug, and yeah, ending off on the financial, as we mentioned in our prepared remarks, we expect both Q1 2023 and FY’23 adjusted EBITDA to be in the mid 20% range. On our last earnings call we mentioned that we contemplated making marketing investments neither in the fourth quarter or this quarter and the first quarter since the timing works for when consumers make decisions around health plans, new plan year start, etc. it’s a great time to reach them. We didn’t make those investments extensively in the last quarter, but we’re still exploring making them as new consumers have fresh deductibles in the start of the year, so around now. Looking forward, we continue to be really focused on driving adjusted EBITDA and cash conversions, while also delivering efficient growth.
So we’re going to continue to take actions that drive shareholder value in those ways. You’ve seen us reduce marketing as a percent of revenue. That’s been an opportunity to drive EBITDA, manage headcounts that are risked, and also through the continued limiting and careful hiring that we’re doing. And you’ve seen us sell off GoodRx care assets that didn’t impact our consumer experience, but reduced the amount of OpEx that it takes for us to maintain them and led us to even more asset light. Those are all actions that we’ve taken in support of increasing dollar EBITDA with that Q-over-Q as the business grows. From a margin perspective, we still think we have room to go and we believe that we can expand our margins over time through the continued growth.
The growth rate issue is volume and revenue impact means it’ll take us a bit a longer to do that. In fact given that our business now has a more fixed cost base than it ever has historically through the risks, through the care and other initiatives we’ve taken, it means that the incremental dollars and growth we’re able to achieve will likely contribute to incremental margin, both in dollars and in percent’s going forward in the out years to come.
Craig Hettenbach: Got it. Thank you.
Karsten Voermann: Sure Craig.
